Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. VP of Sales & Marketing | April 18, 2018 | April 20, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date April 18, 2018 · Filed April 20, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,344 |
Ending reported balance
After 2018-04-19 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2018-04-18 · Exercise / conversion · Acquired 6,250 · Balance 15,594 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Row 2 · 2018-04-18 · Exercise / conversion · Acquired 3,750 · Balance 19,344 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Row 3 · 2018-04-18 · Sale · Disposed 10,000 · Balance 9,344 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Row 4 · 2018-04-19 · Exercise / conversion · Acquired 7,850 · Balance 17,194 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Row 5 · 2018-04-19 · Sale · Disposed 7,850 · Balance 9,344 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.98 · Expires 2026-03-01 | Direct | 25,000 |
Reported balance
After 2018-04-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-04-18 · Exercise / conversion · Disposed 6,250 · Balance 25,000 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F4: The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2027-02-24 | Direct | 46,250 |
Reported balance
After 2018-04-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-04-18 · Exercise / conversion · Disposed 3,750 · Balance 46,250 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F5: The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.30 · Expires 2027-02-24 | Direct | 38,400 |
Reported balance
After 2018-04-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-04-19 · Exercise / conversion · Disposed 7,850 · Balance 38,400 F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F5: The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4: The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted.
F5: The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 19, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 7,850 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · derivative · entry 8 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,400 Underlying: Common Stock · 7,850 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 7,850 | $49.03 | $384,854.89 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · nonDerivative · entry 5 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.00 to $49.15, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| April 19, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 7,850 | $25.30 | $198,605.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · nonDerivative · entry 4 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · derivative · entry 7 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,250 Underlying: Common Stock · 3,750 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 24, 2018, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · derivative · entry 6 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 10,000 | $47.06 | $470,617.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · nonDerivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.25, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 3,750 | $25.30 | $94,875.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Read SEC document |
| April 18, 2018 Filed Apr 20, 2018 20:53 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 6,250 | $12.98 | $81,125.00 |
DisclosureSEC source: 0001104659-18-025639 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales & Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 18,750 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · derivative · entry 9 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 18,750 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F5 · derivative.exercise_date: The option became exercisable in four equal installments beginning on March 1, 2017, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $9.13 | $0.00 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · derivative · entry 8 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 26,250 shares Expires 2025-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on March 3, 2016, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · derivative · entry 7 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 18,750 | $45.33 | $849,928.13 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · nonDerivative · entry 6 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.1500 to $45.9750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 18,750 | $12.98 | $243,375.00 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · nonDerivative · entry 5 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 26,250 | $45.33 | $1,189,899.38 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · nonDerivative · entry 4 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.1500 to $45.9750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 26,250 | $9.13 | $239,662.50 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · nonDerivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $45.33 | $679,942.50 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.1500 to $45.9750, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| April 05, 2018 Filed Apr 9, 2018 16:12 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $9.24 | $138,600.00 |
DisclosureSEC source: 0001104659-18-023012 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales and Marketing 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted March 6, 2018. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:58 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 33,000 | $0.00 Strike: $39.40 | $0.00 |
DisclosureSEC source: 0001104659-18-010412 · a4.xml · derivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 14, 2019. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $9.24 | $0.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · derivative · entry 6 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2024-01-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on January 21, 2015, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,250 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · derivative · entry 5 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $47.03 | $705,499.50 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 4 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.00 to $47.10, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $9.24 | $138,600.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 9,250 | $45.00 | $416,250.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 17, 2018 Filed Jan 17, 2018 23:44 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 9,250 | $7.90 | $73,075.00 |
DisclosureSEC source: 0001104659-18-002701 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,594 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,750 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-002401 · a4.xml · derivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 5,750 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 5,750 | $45.03 | $258,927.68 |
DisclosureSEC source: 0001104659-18-002401 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.45, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 21:49 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 5,750 | $7.90 | $45,425.00 |
DisclosureSEC source: 0001104659-18-002401 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,094 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 00:37 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-001524 · a4.xml · derivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 00:37 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 15,000 | $42.04 | $630,649.50 |
DisclosureSEC source: 0001104659-18-001524 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.0000 to $42.4000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. Read SEC document |
| January 09, 2018 Filed Jan 10, 2018 00:37 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 15,000 | $7.90 | $118,500.00 |
DisclosureSEC source: 0001104659-18-001524 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:07 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $7.90 | $0.00 |
DisclosureSEC source: 0001104659-18-000771 · a4.xml · derivative · entry 3 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 55,000 shares Expires 2023-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F4 · derivative.exercise_date: The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:07 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 55,000 | $40.11 | $2,206,308.50 |
DisclosureSEC source: 0001104659-18-000771 · a4.xml · nonDerivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,344 F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.0000 to $40.7000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:07 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 55,000 | $7.90 | $434,500.00 |
DisclosureSEC source: 0001104659-18-000771 · a4.xml · nonDerivative · entry 1 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017. F2 · balance_after: Includes an aggregate of 785 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan subsequent to the date of the Reporting Person's most recent filing on Form 4. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:58 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012177 · a4.xml · derivative · entry 2 Vaughn Victor · CIK 0001567077 · Sr. VP of Sales 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2027-02-24 F2 · derivative.exercise_date: The option vests in four equal installments beginning on February 24, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.